Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT

IntroductionSince allogeneic stem cell transplantation (allo-HSCT) is considered one of the curative treatments for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), hematological relapse following allo-HSCT remained a crucial concern for patients’ survival. MethodsWe retrospectively...

Celý popis

Podrobná bibliografie
Hlavní autoři: Zhangjie Chen, Sisi Zhen, Tingting Zhang, Yuyan Shen, Aiming Pang, Donglin Yang, Rongli Zhang, Qiaoling Ma, Yi He, Jialin Wei, Weihua Zhai, Xin Chen, Erlie Jiang, Mingzhe Han, Sizhou Feng
Médium: Článek
Jazyk:English
Vydáno: Frontiers Media S.A. 2023-03-01
Edice:Frontiers in Oncology
Témata:
venetoclax
myeloid malignancy
acute myeloid leukemia
allo-HSCT
relapse
On-line přístup:https://www.frontiersin.org/articles/10.3389/fonc.2023.1137175/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1137175/full

Podobné jednotky